{"entity":{"id":"hct-conditioning-and-engraftment-care","kind":"protocol","name":"Stem cell transplant: conditioning, the low blood count phase and engraftment monitoring","aka":["haematopoietic cell transplant conditioning","HCT conditioning","HSCT conditioning","bone marrow transplant conditioning","preparative regimen","engraftment monitoring","neutrophil engraftment","platelet engraftment","graft failure","chimerism testing","engraftment syndrome","neutropenic phase after transplant"],"tldr":"Before a stem cell transplant you have conditioning: chemotherapy, sometimes with radiotherapy, usually over 1 to 10 days. It destroys unhealthy blood cells and holds back the immune system so the new cells can settle. For some weeks the blood counts are very low, so the team guards against infection, gives transfusions and checks the blood often until the new cells start working (engraftment).","summary":"This protocol covers the weeks from the start of conditioning to documented engraftment; the reader's own unit's policy comes first. Before conditioning starts, the attending physician confirms that the donor or product is available and suitable, and the regimen is given from standardised orders checked by a pharmacist and verified at the bedside by two people or one person with a validated process (FACT-JACIE 9.1, B7.2 and B7.4, all 'shall' standards). Total body irradiation needs a prior radiation oncology consultation (B7.5.1). Regimen intensity (myeloablative, reduced toxicity, reduced intensity, non-myeloablative) is chosen by age, comorbidity, disease status and measurable residual disease (EBMT Handbook 2024). The 2009 working definitions call a regimen myeloablative when it causes irreversible or nearly irreversible pancytopenia and stem cell support is required (their examples: total body irradiation of 5 Gy or more in a single dose or 8 Gy or more fractionated, or busulfan above 8 mg/kg by mouth or the intravenous equivalent), non-myeloablative when it causes minimal cytopenia and needs no stem cell support (example: total body irradiation of 2 Gy or less with or without a purine analogue), and reduced intensity when it fits neither. High-dose busulfan needs anticonvulsant cover from 12 hours before the first dose to 24 hours after the last, and daily counts until engraftment (label). Two qualified people verify the patient, the product and the order before infusion (B7.6.5). During neutropenia: a single room if possible (2009 global guidelines BIII; a protective environment room with HEPA filtration 'ideally', AIII for the filter), hand hygiene (AII), irradiated cellular blood components (Handbook). On growth factor after transplant the sources differ: the 2009 guidelines make no recommendation (CI); the Handbook advises considering G-CSF where the risk of graft failure is high. Neutrophil recovery is the first of 3 successive days with a count of 500 per microlitre or more; platelet recovery the first of 3 consecutive days at 20,000 per microlitre or more in the absence of platelet transfusion for 7 consecutive days; primary graft failure is no neutrophil recovery by day +30 (blood or marrow grafts) or day +42 (cord blood), with pancytopenia, confirmed by chimerism (EBMT, ASTCT, CIBMTR and APBMT, 2024). Fever with rash or breathlessness around engraftment that is not infection may be engraftment syndrome; the Handbook's authors advise stopping G-CSF, taking cultures and starting broad-spectrum antibiotics, then after 48 hours methylprednisolone 1 mg/kg every 12 hours intravenously for 3 days, tapered over a week.","asOf":"2026-11-17","links":[],"tags":[],"related":["allo-hct-gvhd-prophylaxis","hepatic-veno-occlusive-disease-after-transplant","stem-cell-mobilisation-and-collection","febrile-neutropenia-first-hour","antibacterial-prophylaxis-in-neutropenia","antifungal-prophylaxis-in-haematology","herpes-simplex-and-zoster-antiviral-prophylaxis","pneumocystis-pneumonia-prophylaxis","red-cell-and-platelet-transfusion-thresholds","oral-mucositis-prevention-and-oral-care","food-safety-and-neutropenic-diet","neutropenic-precautions-and-daily-life","vaccination-around-cancer-treatment","car-t-lymphodepletion","filgrastim","melphalan","treosulfan","thiotepa","fludarabine"],"cancers":[],"sections":[],"technologies":["allogeneic-hsct","autologous-stem-cell-transplant","total-body-irradiation"],"targets":[],"drugs":["busulfan"],"companies":[],"institutions":[],"pathways":[],"terms":["conditioning-regimen","neutropenia","gvhd"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"simple":"First you have strong treatment to prepare your body. Then you are given the stem cells through a drip. For some weeks your blood counts are very low, so you usually have a room of your own, staff and visitors clean their hands, and your blood is tested often. When the counts start to rise, the new cells have taken.","domain":"cell-therapy-toxicity","setting":{"who":["doctor","nurse","pharmacist","multidisciplinary-team"],"where":["ward","radiotherapy-department","outpatient-clinic"]},"population":"Adults and children having an autologous (own cells) or allogeneic (donor cells) haematopoietic cell transplant. The FACT-JACIE standards apply to autologous and allogeneic transplant programmes; the 2024 definitions of recovery, graft failure and chimerism were agreed for allogeneic transplants only, by a panel of adult and paediatric transplant physicians. Regimens, doses and schedules differ by disease, donor and unit and are not set out here. This page explains care that a transplant team delivers in hospital; the reader's own team's protocol comes first.","trigger":"A transplant date has been set and the conditioning (preparative) regimen is about to start. The protocol ends when neutrophil and platelet recovery are documented, or graft failure is diagnosed.","steps":[{"action":"Confirm that the donor or the stored cells are available and suitable before the first dose of conditioning","why":"Myeloablative conditioning causes a fall in the blood counts that is usually irreversible unless stem cells are given, so the cells are confirmed before it starts.","source":"fact-jacie-2025","quote":"The attending physician shall confirm the availability and suitability of a donor or cellular therapy product prior to initiating the recipient’s preparative regimen.","grade":"Standard B7.2 (shall)"},{"action":"Choose the intensity of conditioning by the person's age, other illnesses and disease status, including measurable residual disease","why":"Stronger regimens lower the chance of the cancer returning but are harder on the body; gentler ones let older or less fit people have a transplant.","source":"ebmt-handbook-2024","quote":"The conditioning regimen pretransplantation should take into consideration patient and disease characteristics, including age, comorbidities, and disease status, including measurable residual disease."},{"action":"Write the conditioning on preprinted or electronic standard orders, verified by an attending physician, with current height and weight, dates, daily doses and routes","why":"A standard order set, checked by a doctor, makes a mistake in a dose, a date or a route less likely.","source":"fact-jacie-2025","quote":"Preprinted orders or electronic equivalent shall be used for protocols and standardized regimens. These orders shall be verified and documented by an attending physician.","grade":"Standards B7.4.1 and B7.4.2 (shall)"},{"action":"Have the pharmacist check each dose against the protocol when verifying or preparing the drug","why":"An independent check by a second profession catches an error before the drug is made.","source":"fact-jacie-2025","quote":"The pharmacist verifying or preparing the drug shall check and document the dose against the protocol or standardized regimen listed on the orders.","grade":"Standard B7.4.3 (shall)"},{"action":"Before the regimen is given, verify and document the drug and dose against the orders and the protocol, and the identity of the patient, with two qualified people or one using a validated process","why":"This is the last check before the drug reaches the patient: the right drug, the right dose, the right person.","source":"fact-jacie-2025","quote":"Prior to administration of the preparative regimen, one (1) qualified person using a validated process or two (2) qualified persons shall verify and document:","grade":"Standard B7.4.4 (shall)"},{"action":"If the regimen includes total body irradiation, arrange a consultation with a radiation oncologist before treatment starts","why":"The radiotherapy doctor needs to know about earlier radiotherapy and anything else that could make the radiation more harmful, and to plan how it is delivered.","source":"fact-jacie-2025","quote":"There shall be a consultation with a radiation oncologist prior to initiation of therapy if radiation treatment is used in the preparative regimen.","grade":"Standard B7.5.1 (shall)"},{"action":"If the regimen includes high-dose busulfan, give an anticonvulsant from 12 hours before the first dose until 24 hours after the last, and antiemetics on a fixed schedule","why":"High-dose busulfan can cause seizures, and medicine given beforehand prevents them.","source":"busulfex-label","quote":"Premedicate patients with anticonvulsants (e.g., benzodiazepines, phenytoin, valproic acid or levetiracetam) to prevent seizures reported with the use of high dose BUSULFEX. Administer anticonvulsants 12 hours prior to BUSULFEX to 24 hours after the last dose of BUSULFEX","grade":"Prescribing information, section 2.1"},{"action":"Before the cells are infused, have two qualified people verify the identity of the patient, the product and the order","why":"The cells are meant for one person, so two people confirm that the right product is going to the right patient on the right order.","source":"fact-jacie-2025","quote":"Two (2) qualified persons shall verify the identity of the recipient and the product and the order for administration prior to the administration of the cellular therapy product.","grade":"Standard B7.6.5 (shall)"},{"action":"Nurse the patient in a single room where possible while the counts are low","why":"A room of one's own, with filtered air where the unit has it, is meant to lower exposure to infections carried by other people and to mould spores in the air. The guidelines say the effect of specific isolation precautions has not been evaluated in transplant recipients, which is why the grade rests on expert opinion.","source":"global-infection-guidelines-2009","quote":"HCT recipients should be placed in single-patient rooms (BIII), if possible.","grade":"BIII"},{"action":"Clean your hands before and after every contact with the patient, and ask visitors to do the same","why":"The guidelines call hand hygiene the mainstay of preventing infection in hospital, and a person with very few white cells is less able to fight an infection that reaches them.","source":"global-infection-guidelines-2009","quote":"Hand hygiene is the mainstay of infection prevention in the hospital, and is an essential element of Standard Precautions for all patients (AII)","grade":"AII for hand hygiene as the mainstay of infection prevention; BIII for encouraging visitors to clean their hands"},{"action":"After high-dose busulfan, take a full blood count with differential and platelets every day during treatment and until engraftment is shown","why":"The daily count shows when transfusions are needed and is how the first sign of the new marrow working is seen. The label says this for busulfan; for other regimens the FACT-JACIE standards require a policy for monitoring blood counts (B7.7.2) without saying how often.","source":"busulfex-label","quote":"Monitor complete blood counts, including white blood cell differentials, and quantitative platelet counts daily during treatment and until engraftment is demonstrated.","grade":"Prescribing information, section 5.1"},{"action":"Give only irradiated red cells, platelets and granulocytes","why":"Living white cells (T lymphocytes) in donated blood can mount an immune attack on the person receiving it, called transfusion-associated graft-versus-host disease. It is uncommon but very serious, and irradiating the blood is how it is prevented.","source":"ebmt-handbook-2024","quote":"HCT recipients are at a risk of ta-GvHD and should receive irradiated cellular blood products (Kopolovic et al. 2015)."},{"action":"Record neutrophil recovery on the first of 3 successive days, after the lowest point, with a neutrophil count of 500 per microlitre (0.5 × 10⁹/L) or more","why":"An agreed definition lets the team, the patient and the registries mean the same thing by engraftment.","source":"ebmt-astct-definitions-2024","quote":"Both panels endorsed the existing definition of neutrophil recovery as the first of 3 successive days with an absolute neutrophil count of ≥500/μL after post-transplantation nadir.","grade":"Consensus (at least 70% of the panel agreeing)"},{"action":"Record platelet recovery on the first of 3 consecutive days with a platelet count of 20,000 per microlitre (20 × 10⁹/L) or more in the absence of platelet transfusion for 7 consecutive days","why":"A platelet count that holds without transfusion shows the new marrow is making its own platelets.","source":"ebmt-astct-definitions-2024","quote":"Both panels endorsed the definition of platelet recovery as the first of 3 consecutive days with a platelet count of 20,000/μL or higher in the absence of platelet transfusion for 7 consecutive days.","grade":"Consensus (at least 70% of the panel agreeing)"},{"action":"If fever with no infection to explain it, a widespread rash, breathlessness or weight gain appear around the time the counts rise, think of engraftment syndrome: stop G-CSF, take cultures and start broad-spectrum antibiotics; after 48 hours, with the antibiotics continuing, start methylprednisolone 1 mg/kg every 12 hours intravenously for 3 days and taper it over a week","why":"The returning white cells and the chemical signals they release can disturb the lining of small blood vessels. It looks like infection, so infection is treated first; with early steroid treatment the Handbook reports rapid resolution in more than 90% of cases. This is the chapter authors' advice, not a graded recommendation, and if there is no rapid improvement they advise considering other diagnoses.","source":"ebmt-handbook-2024","quote":"Stop G-CSF immediately, obtain cultures, and start broad-spectrum ATB."},{"action":"If the neutrophil count has not reached 500 per microlitre by day +30 after a blood or marrow graft, or day +42 after cord blood, and the other counts are low, assess for graft failure and test donor chimerism","why":"The EBMT Handbook advises acting as soon as graft failure is suspected: stopping as many marrow-toxic drugs as possible, treating infection and trying G-CSF, with donor cells or a second transplant as later options. Chimerism testing confirms the suspicion.","source":"ebmt-astct-definitions-2024","quote":"PBSCs: Both panels defined graft failure as lack of achievement of an ANC ≥500/μL by day +30 with associated pancytopenia.","grade":"Consensus (at least 70% of the panel agreeing)"},{"action":"After a donor transplant, measure donor chimerism in blood or marrow and report it as full (more than 95% donor), mixed (5% to 95%) or absent (less than 5%)","why":"Chimerism shows whether the new blood cells come from the donor, which a blood count alone cannot tell.","source":"ebmt-astct-definitions-2024","quote":"Full: Both panels endorsed the existing definition of full donor chimerism as >95% for both myeloid and lymphoid lineages.","grade":"Consensus (at least 70% of the panel agreeing)"}],"bestInClass":{"statement":"No single graded guideline covers this stretch of care, and the page says which kind of source each part rests on. The safety checks around conditioning and cell infusion are requirements of the FACT-JACIE standards (ninth edition, version 9.1, effective February 2026), which EBMT's 2025 indications paper recommends units work to. The definitions of neutrophil and platelet recovery, graft failure and chimerism are the 2024 consensus of EBMT, ASTCT, CIBMTR and APBMT, which endorsed the 2021 ASTCT definitions with two changes (SI units, and mixed chimerism counted when it affects one lineage). Infection control rests on the 2009 global guidelines, most of whose infection control recommendations are graded III (expert opinion; hand hygiene is AII), and on the EBMT Handbook (2024), a handbook of expert chapters rather than a guideline. On rooms the two differ in emphasis rather than in substance: the 2009 guidelines say recipients should ideally be in protective environment rooms with HEPA filtration, and that the benefit is likely for allogeneic recipients and not well established for autologous ones (BIII); the Handbook repeats that room specification for allogeneic recipients, and adds that there is no consensus on protective (reverse) isolation for neutropenic patients, that a single room with adequate ventilation should be used if possible, and that few centres meet every requirement. On growth factor they differ: the 2009 guidelines make no recommendation on routine use after transplant (CI), while the Handbook advises considering it for people at high risk of graft failure. The words myeloablative, reduced intensity and non-myeloablative are used as the 2009 working definitions set them out. Drug-specific steps (busulfan) come from the manufacturer's label.","sources":["fact-jacie-2025","ebmt-astct-definitions-2024","global-infection-guidelines-2009","ebmt-handbook-2024","ebmt-indications-2025","conditioning-intensity-2009"]},"variants":[{"name":"Protective environment room with HEPA-filtered air and positive pressure","differs":"Places every recipient, rather than only those at highest risk, in a sealed room with at least 12 air changes an hour, HEPA filtration and positive pressure. The 2009 global guidelines state: \"HCT recipients should ideally be placed in Protective Environment rooms that incorporate the following features:\" and, when such rooms are short, give them first to those at highest risk of mould infection (BIII). They add that allogeneic recipients are likely to benefit from a protective environment and that its efficacy for autologous recipients is not well established (both BIII).","evidence":"The EBMT Handbook (2024) repeats the 2009 room specification for allogeneic recipients and says the efficacy of protective isolation after an autologous transplant is less well established. On barrier practices it is more reserved: \"There is no consensus on specific protective environment, also called reverse isolation, for neutropenic patients.\" It notes that HEPA-filtered rooms are available in almost all centres while few centres met every listed requirement, that no clear benefit has been shown for routine footwear exchange, gloves or gowns, and that the effect of strict isolation on quality of life should be weighed. The 2009 guidelines grade the filter AIII and directed airflow, positive pressure, sealing, pressure monitoring and self-closing doors BIII, all expert opinion; the 12 air changes an hour carry no printed grade.","sources":["global-infection-guidelines-2009","ebmt-handbook-2024"]},{"name":"G-CSF after the transplant to speed neutrophil recovery","differs":"Gives a growth factor such as filgrastim from a few days after the infusion until the neutrophil count recovers. Practice differs between units and between autologous and allogeneic transplants.","evidence":"The 2009 global guidelines: \"Therefore, the routine use of growth factors after HCT is controversial and no recommendation for their use can be made (CI).\" They say growth factors shorten neutropenia and may slightly reduce infection but have not been shown to reduce mortality. The EBMT Handbook's graft failure chapter, for people at high risk of graft failure, recommends measures that include to \"consider the use of G-CSF posttransplant, and closely evaluate the engraftment including marrow chimerism studies shortly after transplant (day +14)\", while calling these measures barely supported by well-designed studies. Once graft failure is suspected, the same chapter says: \"although of limited utility, it would be reasonable to trial use of G-CSF\". The Handbook also tells teams to stop G-CSF at once if engraftment syndrome is suspected. ASCO updated its guideline on white cell growth factors in February 2026; it was read as an abstract only, and the abstract states no recommendation on growth factor after a transplant, so it is not used.","sources":["global-infection-guidelines-2009","ebmt-handbook-2024","asco-wbc-growth-factors-2026"]},{"name":"Busulfan dose adjusted to blood levels","differs":"Measures busulfan in the blood after an early dose and adjusts later doses to a target exposure, instead of dosing by weight alone.","evidence":"The US label says that exposure (area under the curve) above 1,500 micromole per min may be associated with a higher risk of hepatic veno-occlusive disease. In its section on use in children, where it says effectiveness has not been specifically studied, it describes dosing aimed at 900 to 1,350 micromole per min and recommends drug level monitoring and dose adjustment after the first dose. The ASBMT Practice Guidelines Committee (2016) set out to grade the evidence and reported that \"the published literature was too heterogeneous and lacked adequately powered and sufficiently controlled studies for this to be feasible\", publishing answers to frequently asked questions instead; only the abstract was read. The EBMT Pharmacist Committee (2024) published a step-by-step guide and, in its abstract, encourages all centres to monitor busulfan levels, describing the evidence linking exposure to outcome as strongest in adults having myeloablative conditioning and present in children in all settings; only the abstract was read, so its targets are not given here. The EBMT Handbook says intravenous busulfan, with more predictable levels than tablets, reduced the need for level testing.","sources":["asbmt-busulfan-2016","ebmt-busulfan-tdm-2024","busulfex-label","ebmt-handbook-2024"]},{"name":"How long irradiated blood components are continued","differs":"Some centres stop irradiated components at a set time after transplant; others continue them for life.","evidence":"The EBMT Handbook (2024): \"There is no consensus on the duration of the use of irradiated blood products in HCT recipients\". It gives standard practice as from at least 2 weeks before stem cell collection until at least 3 months after an autologous transplant, and from conditioning at the latest until at least 6 months after an allogeneic transplant or until immune reconstitution.","sources":["ebmt-handbook-2024"]},{"name":"Diagnostic criteria for engraftment syndrome","differs":"Three published sets of criteria (Spitzer 2001, Maiolino 2003, Grant 2020) weigh fever, rash, lung signs, weight gain and diarrhoea differently and use different time windows around engraftment.","evidence":"The EBMT Handbook reports that the three sets give an incidence anywhere from 7% to 59% after autologous and 10% to 25% after allogeneic transplants, and advises the Maiolino criteria after an autologous transplant and the stricter Spitzer criteria after an allogeneic one, where graft-versus-host disease and infection must be excluded. This is the chapter authors' advice; no guideline grades it.","sources":["ebmt-handbook-2024"]}],"grades":[{"claim":"Confirm donor or product availability and suitability before conditioning starts","grade":"Standard B7.2 (shall)","source":"fact-jacie-2025"},{"claim":"Two qualified people verify recipient, product and order before the cells are given","grade":"Standard B7.6.5 (shall)","source":"fact-jacie-2025"},{"claim":"EBMT recommends that units work to JACIE standards","grade":"Practice recommendation (ungraded)","source":"ebmt-indications-2025","quote":"We also recommend working according to JACIE certification standards to maintain quality in clinical and laboratory practice, including benchmarking of survival outcomes"},{"claim":"Single-patient rooms for transplant recipients where possible","grade":"BIII","source":"global-infection-guidelines-2009"},{"claim":"HEPA filtration with 99.97% efficiency in protective environment rooms","grade":"AIII","source":"global-infection-guidelines-2009"},{"claim":"Alcohol-based hand rub as the preferred method when hands are not visibly soiled","grade":"AII","source":"global-infection-guidelines-2009","quote":"the preferred method of hand hygiene is with an alcohol-based hand rub because of its superior microbicidal activity, reduced drying of the skin, and convenience (AII)"},{"claim":"Routine growth factor after transplant: no recommendation","grade":"CI","source":"global-infection-guidelines-2009","quote":"Therefore, the routine use of growth factors after HCT is controversial and no recommendation for their use can be made (CI)."},{"claim":"Daily showers or baths with a mild soap during and after transplantation","grade":"BIII","source":"global-infection-guidelines-2009","quote":"To optimize skin care, HCT recipients should take daily showers or baths using a mild soap during and after transplantation (BIII)."},{"claim":"Graft failure after cord blood: no neutrophil recovery by day +42 with pancytopenia","grade":"Consensus (at least 70% of the panel agreeing)","source":"ebmt-astct-definitions-2024","quote":"UCB: Both panels defined graft failure as lack of achievement of an ANC ≥500/μL by day +42 with associated pancytopenia."},{"claim":"Mixed donor chimerism is 5% to 95% in one or both of the myeloid and lymphoid lineages (the 2024 revision)","grade":"Unanimous on the second vote","source":"ebmt-astct-definitions-2024","quote":"Mixed donor chimerism as 5%–95% for either one or both myeloid and lymphoid lineages"},{"claim":"Myeloablative conditioning defined by irreversible or nearly irreversible pancytopenia needing stem cell support","grade":"Working definition (expert consensus, no evidence grade)","source":"conditioning-intensity-2009","quote":"A myeloablative conditioning regimen (MA) will cause irreversible (or close to irreversible) pancytopenia. Stem cell support is required to rescue marrow function, and prevent aplasia related death."},{"claim":"Infection control recommendations for transplant recipients rest on expert opinion","grade":"Level III","source":"ebmt-handbook-2024","quote":"Hence, recommendations on infection control could only be graded as level III."}],"sources":[{"key":"fact-jacie-2025","label":"FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing, and Administration, Ninth Edition, version 9.1","publisher":"Foundation for the Accreditation of Cellular Therapy (FACT) and JACIE (ISCT and EBMT)","year":2025,"url":"https://www.ebmt.org/sites/default/files/2025-12/FACT-JACIE%20HCT%20Standards%209th%20Ed_V9-1.pdf","gradingScheme":"Accreditation standards, not graded evidence: 'shall' means the standard is to be complied with at all times; 'should' is recommended or advised, with possible effective alternatives; 'may' is permissive.","read":"full-text","accessed":"2026-11-17"},{"key":"ebmt-astct-definitions-2024","label":"Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT","publisher":"Bone Marrow Transplantation (Sureda et al.)","year":2024,"url":"https://doi.org/10.1038/s41409-024-02251-0","doi":"10.1038/s41409-024-02251-0","gradingScheme":"Modified Delphi: consensus was at least 70% of voting panel members strongly or somewhat agreeing. No evidence grades.","read":"full-text","accessed":"2026-11-17"},{"key":"astct-definitions-2021","label":"Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy","publisher":"Transplantation and Cellular Therapy (Kharfan-Dabaja et al.)","year":2021,"url":"https://doi.org/10.1016/j.jtct.2021.04.007","doi":"10.1016/j.jtct.2021.04.007","read":"abstract","accessed":"2026-11-17"},{"key":"global-infection-guidelines-2009","label":"Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective","publisher":"Biology of Blood and Marrow Transplantation (Tomblyn et al.; CIBMTR, NMDP, EBMT, ASBMT, CBMTG, IDSA, SHEA, AMMI, CDC)","year":2009,"url":"https://doi.org/10.1016/j.bbmt.2009.06.019","doi":"10.1016/j.bbmt.2009.06.019","gradingScheme":"Strength A (should always be offered) to E (should never be offered), with C optional; quality of evidence I (at least one randomised controlled trial), II (non-randomised trials, cohort or case-control studies) or III (expert opinion, descriptive studies).","read":"full-text","accessed":"2026-11-17"},{"key":"ebmt-handbook-2024","label":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies, 8th edition (chapters 13, 21, 22, 24, 27, 41, 42 and 51)","publisher":"EBMT (Springer; Sureda, Corbacioglu, Greco, Kröger and Carreras, editors). A handbook of expert chapters, not a graded guideline","year":2024,"url":"https://www.ncbi.nlm.nih.gov/books/NBK608238/","doi":"10.1007/978-3-031-44080-9","gradingScheme":"None: the chapters give their authors' advice and cite the studies behind it.","read":"full-text","accessed":"2026-11-17"},{"key":"busulfex-label","label":"BUSULFEX (busulfan) injection: US prescribing information (manufacturer's label)","publisher":"Otsuka America Pharmaceutical (industry), on DailyMed, US National Library of Medicine","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cb9d285-1803-4a99-946a-d0b239b32df6","gradingScheme":"A regulator-approved label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"asbmt-busulfan-2016","label":"Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee","publisher":"Biology of Blood and Marrow Transplantation (Palmer et al.)","year":2016,"url":"https://doi.org/10.1016/j.bbmt.2016.07.013","doi":"10.1016/j.bbmt.2016.07.013","read":"abstract","accessed":"2026-11-17"},{"key":"conditioning-intensity-2009","label":"Defining the intensity of conditioning regimens: working definitions","publisher":"Biology of Blood and Marrow Transplantation (Bacigalupo et al.)","year":2009,"url":"https://doi.org/10.1016/j.bbmt.2009.07.004","doi":"10.1016/j.bbmt.2009.07.004","gradingScheme":"Working definitions from an expert workshop; no evidence grades.","read":"full-text","accessed":"2026-11-17"},{"key":"ebmt-busulfan-tdm-2024","label":"A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)","publisher":"Bone Marrow Transplantation (Domingos et al.)","year":2024,"url":"https://doi.org/10.1038/s41409-024-02413-0","doi":"10.1038/s41409-024-02413-0","read":"abstract","accessed":"2026-11-17"},{"key":"asco-wbc-growth-factors-2026","label":"WBC Growth Factors: ASCO Guideline Update","publisher":"Journal of Clinical Oncology (Gyawali et al.; American Society of Clinical Oncology)","year":2026,"url":"https://doi.org/10.1200/JCO-25-02938","doi":"10.1200/JCO-25-02938","read":"abstract","accessed":"2026-11-17"},{"key":"nhs-stem-cell-transplant-2026","label":"Stem cell or bone marrow transplants: how it's done, and recovery (pages last reviewed 7 May 2026)","publisher":"NHS (nhs.uk), patient information","year":2026,"url":"https://www.nhs.uk/tests-and-treatments/stem-cell-or-bone-marrow-transplants/how-its-done/","gradingScheme":"Patient information; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"ebmt-indications-2025","label":"Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations","publisher":"Bone Marrow Transplantation (Greco et al.)","year":2025,"url":"https://doi.org/10.1038/s41409-025-02701-3","doi":"10.1038/s41409-025-02701-3","gradingScheme":"Each indication is placed in a category (among them clinical option and developmental); the statement used here is a general recommendation and carries no grade.","read":"full-text","accessed":"2026-11-17"}],"upgrades":[],"gaps":["No graded international guideline covers the day-to-day nursing and medical care of the conditioning and neutropenic phase as a whole. The steps here are assembled from accreditation standards, a consensus on definitions, a 2009 infection guideline, a handbook and one drug label, and each is marked with its kind of source.","The 2009 global infection guidelines have not been reissued. Most of their infection control recommendations are graded III (expert opinion). The EBMT Handbook (2024) still cites them, repeats their room specification for allogeneic recipients, and says there is no consensus on protective (reverse) isolation for neutropenic patients.","When to measure chimerism is not settled by the sources read. The 2024 harmonisation paper says it did not address timing and points to the 2021 ASTCT paper, which could be read as an abstract only. The EBMT Handbook's follow-up table lists chimerism at 1 and 2 months after an allogeneic transplant and, for people at high risk of graft failure, marrow chimerism at day +14.","The 2024 definitions were agreed for allogeneic transplants. Definitions of delayed engraftment, and of graft failure after G-CSF-stimulated bone marrow, did not reach consensus in 2021 and were not revisited.","Growth factor after transplant: ASCO updated its guideline on white cell growth factors in February 2026. On 17 November 2026 only its abstract could be read (the publisher's page refuses a script), and the abstract states no recommendation on growth factor after a transplant, so the page shows only the 2009 guidelines and the Handbook.","Daily blood counts until engraftment are stated here from the busulfan label, which speaks for that drug only, and whose approved use is busulfan with cyclophosphamide before an allogeneic transplant for chronic myeloid leukaemia. The FACT-JACIE standards require a policy for monitoring blood counts after any regimen (B7.7.2) and set no frequency; no guideline read sets one.","Hydration and mesna with high-dose cyclophosphamide: the EBMT Handbook (chapter 51) says prevention of early bladder bleeding rests on hyperhydration and a continuous intravenous infusion of mesna, and gives no doses or volumes, so none are given here. Supportive schedules for other conditioning drugs (melphalan, thiotepa, treosulfan) and the delivery of total body irradiation were not read for this page.","The 2009 working definitions of conditioning intensity give dose examples for total body irradiation and busulfan only; their table prints no melphalan threshold, so none is given here. The EBMT Handbook notes that newer regimens overlap these classes and that EBMT has proposed a transplant conditioning intensity score (2020), which was not read for this page.","How long the blood counts stay low is not stated as a general figure by any source read. The NHS pages say conditioning usually lasts 1 to 10 days and that people can usually expect several weeks in hospital; the Handbook says myeloablative conditioning causes cytopenia that may last more than 21 days.","The engraftment syndrome treatment, including the methylprednisolone dose, is the advice of the Handbook chapter's authors; no graded guideline on it was found.","The personalised busulfan dosing paper (ASBMT 2016) and the EBMT Pharmacist Committee guide to busulfan monitoring (2024) were read as abstracts only on 17 November 2026 (neither is open access), so their answers on target exposure and sampling are not given here. The only exposure figures on this page are the US label's.","The EBMT Handbook was read from NCBI's open-access archive package. The 2021 ASTCT definitions paper could be read only as an abstract on 17 November 2026 (the journal page returned 403); the definitions on this page are taken from the 2024 paper, which reprints them."]},"route":"/protocols/hct-conditioning-and-engraftment-care/","neighbours":{"protocol":[{"id":"herpes-simplex-and-zoster-antiviral-prophylaxis","kind":"protocol","name":"Aciclovir prophylaxis against herpes simplex and shingles during cancer treatment","route":"/protocols/herpes-simplex-and-zoster-antiviral-prophylaxis/"},{"id":"antibacterial-prophylaxis-in-neutropenia","kind":"protocol","name":"Antibacterial (fluoroquinolone) prophylaxis during expected severe neutropenia","route":"/protocols/antibacterial-prophylaxis-in-neutropenia/"},{"id":"antifungal-prophylaxis-in-haematology","kind":"protocol","name":"Antifungal prophylaxis for people at high risk of invasive fungal infection","route":"/protocols/antifungal-prophylaxis-in-haematology/"},{"id":"food-safety-and-neutropenic-diet","kind":"protocol","name":"Food safety during cancer treatment and the evidence against neutropenic diets","route":"/protocols/food-safety-and-neutropenic-diet/"},{"id":"allo-hct-gvhd-prophylaxis","kind":"protocol","name":"GVHD prophylaxis after allogeneic stem cell transplant: choosing the regimen","route":"/protocols/allo-hct-gvhd-prophylaxis/"},{"id":"ifosfamide-bladder-protection-and-encephalopathy","kind":"protocol","name":"Ifosfamide: bladder protection with mesna and fluids, and ifosfamide encephalopathy","route":"/protocols/ifosfamide-bladder-protection-and-encephalopathy/"},{"id":"veno-occlusive-disease-on-inotuzumab-and-gemtuzumab-ozogamicin","kind":"protocol","name":"Liver toxicity and veno-occlusive disease on inotuzumab ozogamicin and gemtuzumab ozogamicin: risk reduction, monitoring, hold and stop rules","route":"/protocols/veno-occlusive-disease-on-inotuzumab-and-gemtuzumab-ozogamicin/"},{"id":"car-t-lymphodepletion","kind":"protocol","name":"Lymphodepleting chemotherapy before CAR T-cell infusion","route":"/protocols/car-t-lymphodepletion/"},{"id":"oral-mucositis-prevention-and-oral-care","kind":"protocol","name":"Oral care and oral mucositis prevention during cancer treatment","route":"/protocols/oral-mucositis-prevention-and-oral-care/"},{"id":"stem-cell-mobilisation-and-collection","kind":"protocol","name":"Peripheral blood stem cell mobilisation and collection for transplant, in patients and donors","route":"/protocols/stem-cell-mobilisation-and-collection/"},{"id":"pneumocystis-pneumonia-prophylaxis","kind":"protocol","name":"Pneumocystis pneumonia (PJP) prophylaxis with co-trimoxazole","route":"/protocols/pneumocystis-pneumonia-prophylaxis/"},{"id":"neutropenic-precautions-and-daily-life","kind":"protocol","name":"Protective measures and daily life during neutropenia: hand hygiene, visitors, pets, plants, school and swimming","route":"/protocols/neutropenic-precautions-and-daily-life/"},{"id":"red-cell-and-platelet-transfusion-thresholds","kind":"protocol","name":"Red cell and platelet transfusion thresholds in cancer care","route":"/protocols/red-cell-and-platelet-transfusion-thresholds/"},{"id":"febrile-neutropenia-first-hour","kind":"protocol","name":"Suspected febrile neutropenia (neutropenic sepsis): the first hour","route":"/protocols/febrile-neutropenia-first-hour/"},{"id":"vaccination-around-cancer-treatment","kind":"protocol","name":"Vaccination before, during and after cancer treatment","route":"/protocols/vaccination-around-cancer-treatment/"},{"id":"hepatic-veno-occlusive-disease-after-transplant","kind":"protocol","name":"Veno-occlusive disease of the liver (sinusoidal obstruction syndrome) after stem cell transplant: prevention, monitoring, diagnosis and defibrotide","route":"/protocols/hepatic-veno-occlusive-disease-after-transplant/"}],"drug":[{"id":"busulfan","kind":"drug","name":"Busulfan","route":"/drugs/busulfan/"},{"id":"filgrastim","kind":"drug","name":"Filgrastim (G-CSF)","route":"/drugs/filgrastim/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"},{"id":"melphalan","kind":"drug","name":"Melphalan (including hepatic delivery system)","route":"/drugs/melphalan/"},{"id":"thiotepa","kind":"drug","name":"Thiotepa","route":"/drugs/thiotepa/"},{"id":"treosulfan","kind":"drug","name":"Treosulfan","route":"/drugs/treosulfan/"}],"technology":[{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/"},{"id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/"},{"id":"total-body-irradiation","kind":"technology","name":"Total body and total marrow irradiation","route":"/technologies/total-body-irradiation/"}],"term":[{"id":"conditioning-regimen","kind":"term","name":"Conditioning regimen (myeloablative, reduced-intensity)","route":"/terms/conditioning-regimen/"},{"id":"gvhd","kind":"term","name":"Graft-versus-host disease (GVHD) and graft-versus-leukaemia","route":"/terms/gvhd/"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/"}]}}